Kiniksa Pharmaceuticals (KNSA) News Today $27.73 -2.49 (-8.24%) Closing price 06/12/2025 04:00 PM EasternExtended Trading$27.60 -0.14 (-0.49%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why is Kiniksa Pharmaceuticals Dropping Today?Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares have come under pressure following a series of substantial insider sell‐offs by the company’s COO and a board director. COO Eben Tessari reduced his stake by roughly 38%, selling 45,042 shares for $1.37 million and additional tranches of 15,506 and 10,319 shares at about $30.4 per share. Director Barry D. Quart cut his holdings by nearly half, offloading over 27,400 shares across three transactions at prices near $30.3. MarketBeat reports the stock slid about 5.4% in response to the heavy insider selling. Posted 12h agoAI Generated. May Contain Errors. KNSA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Down 5.4% on Insider SellingKiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Down 5.4% Following Insider SellingJune 12 at 1:42 PM | marketbeat.comBarry D. Quart Sells 6,900 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockJune 12 at 8:51 AM | insidertrades.comBarry D. Quart Sells 6,900 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) Director Barry D. Quart sold 6,900 shares of the company's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $30.26, for a total value of $208,794.00. Following the completion of the sale, the director now directly owns 12,546 shares of the company's stock, valued at approximately $379,641.96. This trade represents a 35.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.June 11 at 8:46 PM | marketbeat.comBarry D. Quart Sells 8,212 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) Director Barry D. Quart sold 8,212 shares of the business's stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $30.36, for a total transaction of $249,316.32. Following the sale, the director now directly owns 12,546 shares of the company's stock, valued at approximately $380,896.56. This represents a 39.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.June 11 at 8:46 PM | marketbeat.comEben Tessari Sells 10,319 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 10,319 shares of the firm's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $30.38, for a total value of $313,491.22. Following the transaction, the chief operating officer now owns 72,363 shares of the company's stock, valued at $2,198,387.94. This trade represents a 12.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.June 11 at 8:46 PM | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Director Barry D. Quart Sells 12,336 SharesKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) Director Barry D. Quart sold 12,336 shares of the company's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $30.39, for a total value of $374,891.04. Following the completion of the sale, the director now directly owns 12,546 shares of the company's stock, valued at $381,272.94. The trade was a 49.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.June 11 at 8:46 PM | marketbeat.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells 15,506 Shares of StockKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 15,506 shares of the business's stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $30.46, for a total transaction of $472,312.76. Following the sale, the chief operating officer now directly owns 72,363 shares in the company, valued at approximately $2,204,176.98. This trade represents a 17.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.June 11 at 8:25 PM | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells $1,374,231.42 in StockKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 45,042 shares of the company's stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $30.51, for a total transaction of $1,374,231.42. Following the transaction, the chief operating officer now owns 72,363 shares of the company's stock, valued at $2,207,795.13. This represents a 38.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.June 11 at 8:24 PM | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 12,462 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 28.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institJune 10 at 3:21 AM | marketbeat.comAnalysts Set Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Price Target at $38.80June 10 at 3:11 AM | americanbankingnews.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Reaches New 1-Year High - What's Next?Kiniksa Pharmaceuticals (NASDAQ:KNSA) Hits New 1-Year High - Here's WhyJune 9, 2025 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Cut to "Hold" at Wall Street ZenJune 9, 2025 | americanbankingnews.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock Position Raised by Wellington Management Group LLPWellington Management Group LLP raised its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 46.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 69,813 shares of the company's stock afterJune 7, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Given Average Rating of "Buy" by AnalystsKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) has earned an average recommendation of "Buy" from the five brokerages that are covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating. The average 1 year price target among brokerageJune 7, 2025 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Rating Lowered by Wall Street ZenWall Street Zen lowered shares of Kiniksa Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday.June 7, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Sells $437,316.25 in StockJune 6, 2025 | insidertrades.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Sells 15,211 Shares of StockKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CAO Michael R. Megna sold 15,211 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $28.75, for a total value of $437,316.25. Following the completion of the transaction, the chief accounting officer now directly owns 32,546 shares of the company's stock, valued at approximately $935,697.50. This trade represents a 31.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.June 5, 2025 | marketbeat.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Sells 18,299 Shares of StockKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CFO Mark Ragosa sold 18,299 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $28.80, for a total transaction of $527,011.20. Following the completion of the transaction, the chief financial officer now directly owns 27,009 shares of the company's stock, valued at $777,859.20. This trade represents a 40.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.June 5, 2025 | marketbeat.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Insider Sells 27,594 Shares of StockKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) insider Ross Moat sold 27,594 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $29.02, for a total transaction of $800,777.88. Following the sale, the insider now owns 9,415 shares of the company's stock, valued at approximately $273,223.30. The trade was a 74.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.June 5, 2025 | marketbeat.comKiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent PericarditisJune 5, 2025 | globenewswire.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Sets New 1-Year High - Here's What HappenedKiniksa Pharmaceuticals (NASDAQ:KNSA) Hits New 12-Month High - What's Next?June 4, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Has $4.09 Million Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Hennion & Walsh Asset Management Inc. decreased its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 7.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 184,1June 4, 2025 | marketbeat.com26,808 Shares in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Bought by Squarepoint Ops LLCSquarepoint Ops LLC acquired a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 26,808 shares of the company's stock, valued at approxiJune 4, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Ameriprise Financial Inc.Ameriprise Financial Inc. trimmed its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 70.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 51,076 shares of the company's stock after selling 1June 2, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CEO Sanj K. Patel Sells 4,837 SharesKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CEO Sanj K. Patel sold 4,837 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $27.00, for a total value of $130,599.00. Following the completion of the transaction, the chief executive officer now owns 96,674 shares of the company's stock, valued at approximately $2,610,198. The trade was a 4.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.May 30, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CEO Sells $521,752.17 in StockKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CEO Sanj K. Patel sold 19,317 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $27.01, for a total transaction of $521,752.17. Following the sale, the chief executive officer now owns 96,674 shares of the company's stock, valued at approximately $2,611,164.74. The trade was a 16.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.May 30, 2025 | marketbeat.comSanj K. Patel Sells 62,116 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CEO Sanj K. Patel sold 62,116 shares of the stock in a transaction on Wednesday, May 28th. The stock was sold at an average price of $27.33, for a total value of $1,697,630.28. Following the sale, the chief executive officer now owns 96,674 shares in the company, valued at approximately $2,642,100.42. This represents a 39.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.May 30, 2025 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Price Up 4.2% - Time to Buy?Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Price Up 4.2% - Still a Buy?May 30, 2025 | marketbeat.comKiniksa Pharmaceuticals to Present at Upcoming Investor ConferencesMay 29, 2025 | globenewswire.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CEO Sanj K. Patel Sells 4,837 SharesMay 29, 2025 | insidertrades.comJefferies Financial Group Inc. Raises Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Jefferies Financial Group Inc. lifted its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 39.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 112,400 shares of the company's stock after buyiMay 29, 2025 | marketbeat.comVoloridge Investment Management LLC Trims Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Voloridge Investment Management LLC reduced its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 25.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 140,878 shares of the coMay 29, 2025 | marketbeat.comWoodline Partners LP Reduces Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Woodline Partners LP decreased its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 44.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 19,005 shares of the company's stockMay 29, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Holdings Lifted by Nuveen Asset Management LLCNuveen Asset Management LLC boosted its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 7.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 795,612 shares of the company'May 27, 2025 | marketbeat.comState of Wyoming Takes $293,000 Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)State of Wyoming purchased a new position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 14,806 shares of the company's stock, valueMay 25, 2025 | marketbeat.comMillennium Management LLC Purchases 263,146 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Millennium Management LLC boosted its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 50.9% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 779,672 shares of the company's stock after purchasing an additional 263,14May 25, 2025 | marketbeat.comDeutsche Bank AG Buys 62,083 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Deutsche Bank AG lifted its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 77.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 142,397 shares of the company's stock after buying an additional 62,0May 24, 2025 | marketbeat.comNorthern Trust Corp Raises Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Northern Trust Corp grew its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 11.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 283,599 shares of the company's stock after purchasing an additional 28,3May 23, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells $316,920.00 in StockMay 22, 2025 | insidertrades.comBalyasny Asset Management L.P. Purchases New Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Balyasny Asset Management L.P. purchased a new stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 12,921 shares of the compMay 20, 2025 | marketbeat.comBNP Paribas Financial Markets Has $3.43 Million Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)BNP Paribas Financial Markets lowered its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 10.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 173,480 sharesMay 17, 2025 | marketbeat.comSanj K. Patel Sells 2,872 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockMay 16, 2025 | insidertrades.comParkman Healthcare Partners LLC Boosts Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Parkman Healthcare Partners LLC grew its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 1.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 765,453 shares of the company's stock after buying an additiMay 16, 2025 | marketbeat.comJefferies Financial Group Inc. Has $2.22 Million Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Jefferies Financial Group Inc. increased its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 39.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11May 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 24,463 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 32.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 99,6May 15, 2025 | marketbeat.comHudson Bay Capital Management LP Has $4.45 Million Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Hudson Bay Capital Management LP grew its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 150.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 225,000 shares of the company's stock after buying aMay 15, 2025 | marketbeat.comJane Street Group LLC Has $3.75 Million Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Jane Street Group LLC decreased its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 45.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 189,452 shares of the company'sMay 15, 2025 | marketbeat.comLion Point Capital LP Has $908,000 Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Lion Point Capital LP trimmed its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 25.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 45,900 shares of the company's stock after selling 15,500 shares during the period. KiniMay 14, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Sells 60,900 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Schonfeld Strategic Advisors LLC reduced its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 68.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 28,400 shares of the comMay 13, 2025 | marketbeat.comGranahan Investment Management LLC Sells 44,259 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Granahan Investment Management LLC trimmed its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 8.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 463,110 shares ofMay 12, 2025 | marketbeat.com Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address KNSA Media Mentions By Week KNSA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KNSA News Sentiment▼0.440.88▲Average Medical News Sentiment KNSA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KNSA Articles This Week▼235▲KNSA Articles Average Week Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Blueprint Medicines News Roivant Sciences News Revolution Medicines News BridgeBio Pharma News Elanco Animal Health News Verona Pharma News Legend Biotech News TG Therapeutics News Grifols News Lantheus News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KNSA) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KNSA Stock Free KNSA Stock Alerts